BLU 554

Drug Profile

BLU 554

Alternative Names: BLU-554

Latest Information Update: 30 Nov 2016

Price : $50

At a glance

  • Originator Blueprint Medicines
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Type 4 fibroblast growth factor receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Hepatocellular carcinoma
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Cholangiocarcinoma; Hepatocellular carcinoma

Most Recent Events

  • 26 Nov 2016 Preliminary efficacy and adverse events data from a phase I trial in Hepatocellular carcinoma and Cholangiocarcinoma released by Blueprint Medicines
  • 28 Sep 2015 BLU 554 receives Orphan Drug status for Hepatocellular carcinoma in USA
  • 01 Jul 2015 Phase-I clinical trials in Hepatocellular carcinoma (Inoperable/Unresectable) in United Kingdom, Spain, Singapore, South Korea and Germany (PO) after July 2015 (NCT02508467)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top